openPR Logo
Press release

Alpha 1-Antitrypsin Deficiency Treatment Market: Increased Efficiency of New Therapeutics Assures Higher Adoption

01-12-2017 06:29 AM CET | Health & Medicine

Press release from: TMR

Alpha 1-Antitrypsin Deficiency Treatment Market: Increased

Transparency Market Research presents an analysis of the global alpha 1-antitrypsin deficiency market to its readers. The research report, titled “Alpha 1-Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024,” analyzes the market drivers and restraints impacting the global market.

Additionally, the report also studies the historical data and matches it to the current market scenario to map a trajectory for the global market. The report has been collaborated using primary and secondary research methodologies that ensure accurate and exact assessment of the data.

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13214

Deficiency of alpha 1-antitrypsin is known to be genetic, which, if untreated, can lead to cardiovascular ailments such as chronic obstructive pulmonary disease (COPD). This deficiency can also result in emphysema or cirrhosis. The commonly observed symptoms of alpha 1-antitrypsin deficiency are poor vision issues, tiredness, constant pulmonary infections, and weight loss.

However, increasing awareness about this deficiency and growing support from the government has increased the demand for alpha 1-antitrypsin therapeutics. Currently, the available therapeutics for alpha 1-antitrypsin deficiency are Prolastin, Aralast, and Zemaira. The drugs in the pipeline for treating alpha 1-antitrypsin deficiency are rAAV1-CB-hAAT, POL-6014, and CT-2009.

Analysts predict that North America and Europe to be the leading regional segments in the global market. The high prevalence of alpha 1-antitrypsin deficiency in these regional segments is anticipated to be the key growth driver. This genetic disorder is predominantly seen in amongst Europeans and residents of North America, who are of the European descent. Those belonging to other races are less likely to be affected by this deficiency.

The acceptance of new methods to treat such deficiencies is also projected to contribute towards the adoption of alpha 1-antitrypsin deficiency treatment. The improved efficiency of these therapeutics is also anticipated to increase their demand in the coming years. The research report estimates the overall values of the global market in terms of both revenue and volume to help the readers grasp the growth rate of the market in the near future.

Some of the key players operating in the global alpha 1-antitrypsin deficiency market are rEVO Biologics, CSL Behring LLC, Baxter International Inc., Halozyme Therapeutics, Inc., iBio, Inc., and Grifols Therapeutics, Inc. The research report provides an insightful understanding of the competitive landscape of the global market. It also examines the business and marketing strategies that the companies are likely to implement in the coming years to win bigger market shares.

Browse Research Report: http://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-market.html

Additionally, the report also includes an assessment of the research and development strategies, the investment plans, and mergers and acquisitions strategies of these companies for the coming few years.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alpha 1-Antitrypsin Deficiency Treatment Market: Increased Efficiency of New Therapeutics Assures Higher Adoption here

News-ID: 410005 • Views:

More Releases from TMR

Emerging Opportunities in Logistics Market with Current Trends Analysis
Emerging Opportunities in Logistics Market with Current Trends Analysis
The global Logistics market is estimated to attain a valuation of US$ 15,273.21 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.5% during the forecast period, 2019-2027. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the
Energy Measurement IC Market is expected to reach US$ 8.39 Bn by the end of 2031
According to a Transparency Market Research (TMR) research report, the global energy measurement ic market is likely to expand at a CAGR of 7.4% during the forecast period, 2022 to 2031. This suggests that the market is expected to reach US$ 8.39 Bn by the end of 2031. The study on the energy measurement ic market adopts rigorous and systematic research approaches to understand the growth dynamic of the market. The
STATCOM UPS Market to Register Double Digit Growth Rate of 16% CAGR by 2024
Over the last decade, rising number of industries and utilities are opting for static synchronous compensator or STATCOM UPS instead of static VAR compensator or SVC UPS. Low harmonic emission coupled with high speed of response is accentuating the expansion of India STATCOM UPS market now and in times to come. Playing a crucial role in voltage control and compensation of reactive power, STATCOM UPS is likely to keep its
Thin Wafer Processing and Dicing Equipment Market US$692.5 mn by 2024 - TMR
Transparency Market Research (TMR) estimates that the global thin wafer processing and dicing equipment market has a highly consolidative landscape. Disco Corp. accounted for largest share of 56.4% in 2015 and likely to be dominant in the coming years. This is creating monopoly in the thin wafer processing and dicing equipment market in terms of competitive presence. The other key players such as EV Group, Plasma-Therm LLC, Lam Research Corp,

All 5 Releases


More Releases for Deficiency

Iron Deficiency And Iron Deficiency Anaemia Treatment Market Size Trends and For …
According to Market Research Intellect, the global Iron Deficiency And Iron Deficiency Anaemia Treatment market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The market for treating iron deficiency and iron deficiency anaemia is growing steadily
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM. DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,
Coagulation Factor Deficiency Market Bridging the Gap: A Growing Coagulation Fac …
Coagulation Factor Deficiency Market worth $9.60 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Coagulation Factor Deficiency Market- (By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologics, Desmopressin, and Others), By End
Alpha-1 Antitrypsin Deficiency and Lung Health Beyond Deficiency Breathing New L …
Alpha 1 Lung Disease Market to Record an Exponential CAGR of 19.33% by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Alpha 1 Lung Disease Market - (By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others), By
Global Iron Deficiency Anaemia Treatment Market to be Driven by the Rising Preva …
The 'Global Iron Deficiency Anaemia Treatment Market Size, Report and Forecast 2023-2031' by Expert Market Research gives an extensive outlook of the global iron deficiency anaemia treatment market, assessing the market on the basis of its segments like drug type, route of administration, treatment channel, and major regions. Iron Deficiency Anaemia Treatment Market Size, Share, Price Trends, Industry Report, Key Players, Major Segments, and Forecast The key highlights of the report include: Market
Growth Hormone Deficiency (GHD) Treatment Market
Growth Hormone Deficiency (GHD) Treatment Market: Overview The growth hormone deficiency (GHD) treatment market has made some notable strides on the back of the growing role of GH replacement therapy in managing GHD in adults. Advances in understanding clinical syndrome of GHD and understanding of diagnosis are key trends boosting the GHD treatment market. Clinical practices pertaining to pharmacological management of the syndrome in the GHD treatment market have made remarkable